Rainier Acquisition Corp.
RNAQ
NASDAQ10.05
USD
+0.02
- -
Rainier Acquisition Corp.
RNAQ
(NASDAQ)
Recent
price
10.05
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Rainier Acquisition Corporation is a Cayman Islands-domiciled special purpose acquisition company focused on identifying and partnering with category-defining life sciences companies to create long-term public-market value through scientific rigor, global sourcing and disciplined execution. Founded in 2023 and headquartered in New York, New York, the company operates through a unit structure that combines one Class A ordinary share and one-fourth of one redeemable warrant; its warrants are exercisable at $11.50 per share, and its securities trade on Nasdaq under the symbols RNAQU, RNAQ and RNAQW. The company’s strategy targets life sciences businesses across therapeutics, diagnostics, genomics, precision medicine, life-science tools and related healthcare technologies, with a focus on public and private market opportunities in the United States and other global markets. Recent company developments include the full exercise of the underwriter’s over-allotment option in its initial public offering, increasing total gross proceeds to $86.25 million, and the announced separation of its IPO units so that Class A ordinary shares and warrants can trade separately beginning September 15, 2026. The company is led by a management team and board with extensive experience in healthcare investing, capital markets, SPAC formation and biotechnology transactions, and it maintains its principal executive offices at 1 Penn Plaza, 48th Floor, New York, NY 10119.